bladder cancer
Zusduri Approved for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer
The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent ...
JUNE 13, 2025
Nivolumab Scores in Bladder and Renal Cancer Trials
Providing adjuvant nivolumab after radical resection continues to yield clinically meaningful disease-free survival ...
APRIL 16, 2025
FDA Approves Imfinzi for Muscle-Invasive Bladder Cancer
The FDA has approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, ...
MARCH 31, 2025
Adding Checkpoint Inhibitor to Therapy Improves Overall Survival in Bladder Cancer
In patients with muscle-invasive bladder cancer (MIBC) eligible for neoadjuvant cisplatin-based chemotherapy ...
OCTOBER 16, 2024
Anktiva Approved for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience) with Bacillus Calmette-Guérin ...
APRIL 24, 2024
Ferring Announces Full Availability of Adstiladrin in the U.S.
Ferring Pharmaceuticals announced that Adstiladrin is now fully available across the U.S. for adults with ...
JANUARY 19, 2024
Study Provides New First-Line Standard for Advanced Bladder Cancer
Clinicians have a new first-line standard for advanced bladder cancer, according to an international phase 3 study, ...
NOVEMBER 7, 2023
Trastuzumab Deruxtecan Demonstrates Benefit Across an Array of HER2-Expressing Tumors
The antibody–drug conjugate trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo/AstraZeneca) is emerging ...
JULY 7, 2023
Improving Outcomes in Patients With Bladder Cancer
The immunotherapy nivolumab (Opdivo, Bristol Myers Squibb) after surgery increased bladder cancer patients’ ...
MARCH 29, 2023
FDA Approves Adstiladrin, First Gene Therapy for Bladder Cancer
Adstiladrin is the first gene therapy for adults with high-risk bacillus Calmette-Guérin-unresponsive ...
DECEMBER 21, 2022
Circulating Extracellular Vesicle Biomarkers May Detect Early-Stage Cancers
A “liquid biopsy” that identifies tumor protein biomarkers found in circulating extracellular vesicles ...
APRIL 19, 2022
Padcev Granted Regular Approval for Locally Advanced or Metastatic UC
The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat some adults with locally advanced or ...
JULY 19, 2021
